Terms: = Lung cancer AND HIP1, ILWEQ, 3092, ENSG00000127946 AND Treatment
11 results:
1. Therapeutic Advances of Rare ALK Fusions in Non-Small Cell lung cancer.
Xiang Y; Zhang S; Fang X; Jiang Y; Fang T; Liu J; Lu K
Curr Oncol; 2022 Oct; 29(10):7816-7831. PubMed ID: 36290895
[TBL] [Abstract] [Full Text] [Related]
2. Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and hip1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.
Ning S; Shi C; Zhang H; Li J
Medicine (Baltimore); 2021 Dec; 100(51):e27999. PubMed ID: 34941039
[TBL] [Abstract] [Full Text] [Related]
3. Clinicopathological features and resistance mechanisms in hip1-ALK-rearranged lung cancer: A multicenter study.
Kang J; Deng QM; Peng KC; Li P; Zhu BT; Wang P; Chu XP; Zhong WZ; Chen HJ; Wang WX; Chen HF; Rao CZ; Xu CW; Yang JJ
Genes Chromosomes Cancer; 2022 Apr; 61(4):177-186. PubMed ID: 34687488
[TBL] [Abstract] [Full Text] [Related]
4. Population pharmacokinetics of the anti-PD-1 antibody camrelizumab in patients with multiple tumor types and model-informed dosing strategy.
Wang CY; Sheng CC; Ma GL; Xu D; Liu XQ; Wang YY; Zhang L; Cui CL; Xu BH; Song YQ; Zhu J; Jiao Z
Acta Pharmacol Sin; 2021 Aug; 42(8):1368-1375. PubMed ID: 33154554
[TBL] [Abstract] [Full Text] [Related]
5. Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes.
Tian P; Liu Y; Zeng H; Tang Y; Lizaso A; Ye J; Shao L; Li Y
J Cancer Res Clin Oncol; 2020 Apr; 146(4):935-944. PubMed ID: 31894386
[TBL] [Abstract] [Full Text] [Related]
6. Thoracic Oncology Multidisciplinary Clinic Reduces Unnecessary Health Care Expenditure Used in the Workup of Patients With Non-small-cell lung cancer.
Voong KR; Liang OS; Dugan P; Torto D; Padula WV; Senter JP; Lang M; Hooker CM; Feliciano J; Broderick S; Yarmus L; Khanna K; Narang A; Hales RK
Clin Lung Cancer; 2019 Jul; 20(4):e430-e441. PubMed ID: 30956040
[TBL] [Abstract] [Full Text] [Related]
7. Identification of a novel hip1-ALK fusion variant in Non-Small-Cell lung cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
[TBL] [Abstract] [Full Text] [Related]
8. A novel fusion of TPR and ALK in lung adenocarcinoma.
Choi YL; Lira ME; Hong M; Kim RN; Choi SJ; Song JY; Pandy K; Mann DL; Stahl JA; Peckham HE; Zheng Z; Han J; Mao M; Kim J
J Thorac Oncol; 2014 Apr; 9(4):563-6. PubMed ID: 24736082
[TBL] [Abstract] [Full Text] [Related]
9. hip1-ALK, a novel ALK fusion variant that responds to crizotinib.
Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
[TBL] [Abstract] [Full Text] [Related]
10. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Cuzick J; Sestak I; Baum M; Buzdar A; Howell A; Dowsett M; Forbes JF;
Lancet Oncol; 2010 Dec; 11(12):1135-41. PubMed ID: 21087898
[TBL] [Abstract] [Full Text] [Related]
11. Intensification of chemotherapy for the treatment of solid tumours: feasibility of a 3-fold increase in dose intensity with peripheral blood progenitor cells and granulocyte colony-stimulating factor.
Leyvraz S; Ketterer N; Perey L; Bauer J; Vuichard P; Grob JP; Schneider P; von Fliedner V; Lejeune F; Bachmann F
Br J Cancer; 1995 Jul; 72(1):178-82. PubMed ID: 7541235
[TBL] [Abstract] [Full Text] [Related]
